StreetInsider.com News Articles

Study finds rapid genome sequencing boosts pediatric diagnoses at Seattle Children's

Mon, 24 Aug 2026 08:34:30 -0400

GeneDx (Nasdaq: WGS) has announced findings from a study published in Genetics in Medicine showing that hospital-wide implementation of rapid genome sequencing (rGS) across inpatient pediatric care units improved diagnostic rates at Seattle Children's hospital.

The study, conducted in collaboration with the clinical genetics team at Seattle Children's, evaluated more than 1,000 pediatric inpatients who received rGS across the neonatal intensive care unit, pediatric intensive care unit, cardiac intensive care unit, and non-critical care inpatient wards over a 3.5-year period.

Key findings included a 35% overall diagnostic yield, with non-ICU inpatient wards recording the highest rate at 43%. Children evaluated for faltering

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data published in Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), in collaboration with the clinical genetics team at Seattle Children’s. The study demonstrates that

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Mon, 24 Aug 2026 08:30:00 -0400

Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis

Children experiencing faltering growth saw striking 63% diagnostic yield

Form SCHEDULE 13G GeneDx Holdings Corp. Filed by: GOLDMAN SACHS GROUP INC

Tue, 11 Aug 2026 19:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26907510.html

Form SCHEDULE 13G GeneDx Holdings Corp. Filed by: GOLDMAN SACHS GROUP INC

Tue, 11 Aug 2026 19:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26907510.html

GeneDx launches online exome testing access for pediatric patients

Tue, 11 Aug 2026 08:31:02 -0400

GeneDx (Nasdaq: WGS) has launched an online offering that allows families to initiate exome genetic testing directly through its website, targeting pediatric patients with global developmental delay, intellectual disability, or epilepsy who face barriers to specialty care.

The service connects families with licensed healthcare providers who can review medical information, order testing, and deliver results without requiring in-person visits. The offering is available to eligible pediatric patients across the United States, subject to provider availability, clinical appropriateness, and applicable state requirements.

According to the company's press release, approximately 25% of pediatric patients wait more than a year and about 50% wait more

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

Tue, 11 Aug 2026 08:30:00 -0400

New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy.